Companies

Akeso

3 articles

Industry NewsSummit Therapeutics / AkesoBioSpace

FDA rejects Summit's ivonescimab in EGFR-mutated lung cancer, citing missing survival benefit

  • FDA issued a complete response letter for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy, which would have been the first US approval of a PD-1xVEGF bispecific.
  • The agency said progression-free survival gains without a statistically significant overall survival benefit do not show a positive benefit-risk profile; HARMONi missed its OS endpoint, and Summit's September follow-up analysis did not change that.
  • Summit says it will keep building evidence across several NSCLC settings and gave no next step for this indication; partner Akeso already markets the drug in China.
PointsBased on public reports

The rejection was widely expected, and the lesson is about trial design: a PFS-only win in a post-TKI setting will not clear today's FDA. The bigger pivot is the Western first-line HARMONi-3 readout, which now carries the whole US thesis, and the combination partners lined up with Summit (AstraZeneca, Pfizer, Revolution Medicines) are holding options, not commitments.

Industry NewsAkeso / Summit TherapeuticsEndpoints News

Akeso details ivonescimab's survival win in biliary tract cancer, a China-only trial

  • Akeso presented HARMONi-GI1 at ESMO 2026: its PD-1xVEGF bispecific ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line advanced biliary tract cancer.
  • The 682-patient study ran in China only and was sponsored and analyzed by Akeso; overall survival was the key result.
  • Summit Therapeutics holds rights outside China, and the data are already prompting Keytruda comparisons.
PointsBased on public reports

An overall-survival win over an anti-PD-1/L1 backbone is the claim PD-1xVEGF bispecifics need, and biliary cancer is a small, low-risk place to show it. But a China-only, Akeso-run trial will not settle Western regulators, so the value to Summit hinges on global trials such as its lung program, not on this readout.

Industry NewsAkeso / Summit TherapeuticsEndpoints News

Ivonescimab Beats Keytruda on Survival in Phase 3 NSCLC Trial

  • Ivonescimab (Akeso/Summit's PD-1 x VEGF bispecific) reduced risk of death by 27% vs. Merck's Keytruda in the Phase 3 HARMONi-2 trial.
  • Trial enrolled treatment-naive, PD-L1-positive advanced NSCLC patients in China.
  • Median overall survival: 30.75 months for ivonescimab vs. 22.57 months for Keytruda.
  • Adds to the trial's earlier primary PFS win — a 49% reduction in progression/death risk (11.14 vs. 5.82 months).
  • Fourth Phase 3 ivonescimab readout to hit its OS endpoint, bolstering the case for combining PD-1 blockade with anti-VEGF activity in one bispecific.
  • Akeso (China) and Summit Therapeutics (ex-China licensee) are co-developing the drug as a head-to-head Keytruda challenger.
PointsBased on public reports

A head-to-head overall-survival win over Keytruda is about as rare an event as oncology drug development produces — Merck's franchise has fended off nearly every direct challenger for a decade, and ivonescimab is now four-for-four on OS across its Phase 3 program. That changes the calculus for Summit, whose ex-China license from Akeso looked speculative at signing and now looks like one of the shrewder biotech deals in recent memory — every data cut adds leverage for future pricing, partnering, or M&A conversations. It's also the clearest advertisement yet for the China-originated-asset licensing wave Western biotechs have been chasing: a domestically-developed bispecific outrunning the world's best-selling drug in its own trial. For Merck, it lands squarely as Keytruda nears patent cliff — this isn't a niche subtype win, it's a direct share threat in frontline NSCLC, the franchise's core indication.